Trending Health

In this episode, Mindy, Ryan, and Jen discuss recent newsworthy items, including the FDA approval of Rejoyn, the first prescription digital treatment for major depressive disorder. They also discuss the ongoing drug shortage crisis, as well as changes coming out of the Centers for Medicare & Medicaid Services and the impact those decisions will have over the next year. Podcast Tags: healthcare, healthcare news, life sciences, health policy, public health, depression, mental health, digital treatment, drugs, pharmaceuticals, shortages, medications, FDA, CMS, Medicare Advantage, breakthrough technology, medical devices Source Links: FDA clears first digital treatment for depression, but experts caution that research is still earlyNumber of ongoing US drug shortages reaches new high, pharmacist group saysFDA commissioner tells lawmakers his agency needs more authority to prevent drug shortagesCMS final rule on broker comp, health equity could shake up Medicare AdvantageMedicare official says breakthrough device reimbursement rule coming in early summer Panel – Jen Burke, Mindy McGrath, Ryan Hummel Research & Production – Anna Briccetti, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

While the health industry is not always an early adopter of new technologies, the growth of generative artificial intelligence (GenAI) has empowered organizations to start transforming their AI aspirations into actions. In this episode, Mindy and Jen are joined by Vynamic’s Innovation Lead, Michael Hudson, and Responsible AI Lead, Todd Quartiere, to discuss where we see health organizations experimenting with AI and what it will take for them to achieve their long-term AI ambitions. To learn more about implementing AI within your organization, check out our recent insight: Why AI fails or flourishes: The underestimated role of culture. Podcast Tags: health, healthcare, healthcare news, generative AI, innovation, responsible use, ChatGPT Source Links: The Unexpected Winners of the ChatGPT Generative AI RevolutionGenerative AI in healthcare: Emerging use for careUS healthcare leadership: How to respond and thriveHow Can AI Improve Health Care?Envisioning Healthcare in a Post-COVID-19 WorldThree-quarters of health professionals project widespread AI adoption5 Key Healthcare Industry Trends to Watch in 2024What Do We Mean When We Talk About “AI Democratisation”? Panel – Jen Burke, Michael Hudson, Mindy McGrath, Todd Quartiere Research & Production – Danielle Lewis, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this Trending News Europe episode, Jack, Jen, and Ollie discuss recent newsworthy items from across Europe, including the impact of and deterrents against “no shows” at medical appointments, the role bacteria play in cancer treatment, and inequalities in the rare disease market, along with the steps being taken to ease these issues. Podcast Tags: healthcare, healthcare news, life sciences, public health, France, medical, bacteria, cancer, immunotherapy, chemotherapy, microbiome, rare disease, Germany, Italy, health disparity Source Links: Dutch hospitals use AI to solve no-show patient problems that cost them millionsCancellations of NHS care are having serious impacts on two-thirds of patientsWould charging patients for missed appointments help fund the NHS?GP \’no shows\’ cost Norfolk NHS more than 1m in a one monthFrance planning €5 no-show fees in a bid to improve community healthcareFrance divided over ‘no-show tax’ for patients failing medical appointments Researchers compile detailed catalog of bacteria living in cancer metastasesBoehringer builds out cancer capabilities with $500M deal for bacteria-focused Swiss biotechThe key to young onset bowel cancer may be gut bacteriaThe mystery of microbes that live inside tumoursDiversity of Bacteria in Cancer MetastasesIt’s the Little Things: A Role for Bacteria in Cancer Treatment The UK is missing out on EU collaboration to improve treatment for rare diseasesOvercoming the burden of rare diseases in EuropeStronger together in the fight against rare diseasesIs Europe on track to be the leader in rare diseases?Right here, right now European public health policies must start giving people living with rare diseases a fair chanceNew rare diseases action plan on horizon, Europe at turning pointEurope needs new 360 rare diseases strategy Panel – Jack Young, Jen Burke, Ollie May Research & Production – Karan Pandya Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In recent years, we’ve seen an increasing number of Life Sciences companies publicly declare commitments to sustainability efforts as a result of increased pressure from governments, customers, and research. Trending Health UK’s Ollie May sits down with two members of Vynamic’s Sustainability Council, Rosanna Vellacott and Matt O’Dell, to discuss why pharmaceutical organizations should be paying attention to sustainability goals, some innovative practices underway, and what leaders should be considering as they embed more sustainable practices into their organizations. Podcast Tags: healthcare, life sciences, sustainability, healthcare news, climate change, climate crisis, emissions, net zero, supply chain Source Links: Striving for sustainable drug discovery using Green ChemistryAccelerating the transition to net zero in life sciencesProcess Digital Twin for PharmaSanofi harnesses Dassault\’s digital twin tech to optimize production at future vaccine plantsStrategies for Sustainability in the Global Pharmaceutical Supply ChainBayer: Improving Sustainability Practices in the Supply ChainBayer: Commitments in Action Creating a Sustainable Product SupplyMaking biopharma’s supply chains more environmentally sustainableThe pharma companies working towards supply chain sustainabilityCarbon footprint of the global pharmaceutical industry and relative impact of its major playersThe Greenhouse Gas Protocol: Technical ReportUnderstanding pharma’s challenges and opportunities in relation to the climate crisisPharmaceutical Company Targets and Strategies to Address Climate Change: Content Analysis of Public Reports from 20 Pharmaceutical CompaniesPharma’s path to Net Zero: Targeting Scope 3 emissions Panel – Oliver May, Rosanna Vellacott, Matt O’Dell Research & Production – Adrea Cope, Everly Petruzzelli, Oliver May Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this Trending News US episode, Jen, Mindy, and Ryan discuss recent newsworthy items, including the introduction of rebate credits by CVS to account for more biosimilars entering the market, as well as a recent ruling by a federal appeals court that drugmakers cannot restrict 340B program offerings from community and specialty pharmacies. Finally, we discuss a groundbreaking procedure in which a kidney from a CRISPR gene edited pig was transplanted into a human. Podcast Tags: healthcare, healthcare news, CVS health, PBMs, biosimilars, 340B, pharmacies, hospitals, providers, xenotransplantation, CRISPR, gene editing Source Links: As Humira biosimilars take over the market, CVS has created a new ploy; the drug “rebate credit”Federal appeals court sides with 340B contract pharmaciesAmerican Hospital Association 340B FactsheetGene edited pig kidney transplanted into a living patient for the first timeKidney Disease Statistics for the United States Panel – Jen Burke, Mindy McGrath, Ryan Hummel Research & Production – Anna Briccetti, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

One of the core tenets of the omnichannel philosophy is continuous learning and refinement – bringing together experience and data to evolve the marketing and model. Jen is joined by Vynamic’s Customer Experience Transformation Lead Mike Zapiec and Omnichannel Offering Lead Josh Padams to discuss what we’ve learned partnering with clients to build their omnichannel capabilities and what Life Sciences organizations can do to take their customer engagement to the next level. For more information on Vynamic’s work in Customer Experience Transformation, check out our service page: https://vynamic.com/what-we-do/services/customer-experience-transformation-cxt/ Podcast Tags: omnichannel, customer engagement, customer experience, marketing, healthcare, life sciences Panel – Mike Zapiec, Josh Padams, Jen Burke Research & Production – Danielle Lewis, Hannah Yee, Aisling McAtamney, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this episode, Jack, Ollie, and Jen discuss a substantial investment package in the UK’s Life Sciences and manufacturing sectors, the role of an AI chatbot in bridging Europe\’s mental health care gap, and how Spain is reshaping pharmaceutical supply chains in Europe. Podcast Tags: healthcare, Europe, healthcare news, manufacturing, research, AI, chatbots, mental health, patient care, Spain, supply chain Source Links: UK lacks plans to make pandemic vaccines quickly, MPs hearSpring Budget puts UK on fast-track to becoming science and technology superpowerUK Spring Budget allocates funds to life sciences manufacturing£360 million to boost British manufacturing and R&DABPI response to the BudgetUK Chancellor trumpets £650m AstraZeneca investmentMeet the AI chatbot therapists filling the gaps in Europe’s mental health care shortfallMental health services facing ‘vicious cycle’ workforce issueA chatbot helped more people access mental-health servicesClosing the accessibility gap to mental health treatment with a personalized self-referral chatbotA child in Poland has to wait 238 days to see a psychiatrist, activist saysFrom ‘crisis’ to ‘pandemic’: mental health in EuropeEurope\’s mental health crisis: Which country uses the most antidepressants?Belgium leads the charge on the EU’s medicines reshoring plansEU capitals propose Chips Act for medicinesOnshoring and global health – has the pandemic sent globalisation into reverse?France\’s Emmanuel Macron seeks to relocate domestic production of key drugs to avoid shortagesBarcelona identified as Europe’s second-best hub for biotech investmentModerna opens international centre for analytical excellence in MadridSpain showing great pharma potential as Barcelona named Europe’s No.2 hub for biotech investmentSpain Has All the Right Elements To Become a Fast-Growing Life Science HubSpain’s plan to become Europe’s pharmaceutical epicentre Panel – Jack Young, Jen Burke, Ollie May Research & Production – Jack Young, Karan Pandya, Ollie May Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

The obesity drug market has grown dramatically in the last few years, especially with the help of social media and influencers. The immense popularity of anti-obesity medications has transformed a health industry development into a cultural phenomenon. While this market has so much opportunity, it also faces supply issues and coverage gaps. Mindy and Jen are joined by Vynamic’s Head of Life Sciences, Karen Baldry, and Head of Health Plans, Saurabh Raman, to talk about the growth and challenges obesity medications present for the health industry. Podcast Tags: healthcare, obesity, weight loss, diabetes, health services, health plans, life sciences Source Links: What Is Ozempic and Why Is It Getting So Much Attention?We Know Where New Weight Loss Drugs Came From, but Not Why They WorkWhat the Scientists Who Pioneered Weight-Loss Drugs Want You to KnowSupply Updates about WegovyThe increase in appetite for obesity drugsDemand for GLP-1 drugs is growing. Here\’s why payers are hesitant to cover them for weight lossMore than 4,000 ads for Ozempic-style drugs found running on Instagram and Facebook Wegovy heart health data is promising — but insurers face long road, high cost to cover obesity drugsMedicare is barred from paying for weight-loss drugs like Wegovy. Lawmakers just took the first step to change thatCost isn’t the only reason Medicare doesn’t cover WegovyNew marketing push by Ozempic and others sparks body-positive backlashWhat You Need to Know About Compounded Versions of Popular Weight Loss DrugsNovo antes up $16.5B to poach CDMO giant Catalent amid Wegovy surgeWegovy, other GLP-1s could lower heart disease: StudyNovo kidney trial finds Ozempic cuts cardiac deaths in diabeticsHow Ozempic and Weight Loss Drugs Are Reshaping Denmark’s EconomyNovo Nordisk\’s Wegovy bonanza looms large in DenmarkBig pharma’s blockbuster obesity drug battle is just getting started, and it’s headed for $100 billionLilly Launches End-to-End Digital Healthcare Experience through LillyDirectOzempic vs WegovyObesity drug boom pushes Novo Nordisk shares to record highPopular use of obesity drugs like Ozempic could change consumer habits Panel – Jen Burke, Mindy McGrath, Karen Baldry, Saurabh Raman Research & Production – Adrea Cope, Everly Petruzzelli Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

Since it was signed into law in 2022, the health industry has been abuzz about the longer-term impact of the Inflation Reduction Act. In this episode, Jen & Mindy sit down to discuss recent headlines and developments around this landmark legislation and what Life Sciences companies should expect over the course of the next year. For more perspective on the Inflation Reduction Act\’s impact on Life Sciences companies, check out Mindy’s article in Pharmaphorum, "Seizing the moment: The life sciences industry at the threshold of change”. Podcast Tags: healthcare, healthcare news, life sciences, health policy, inflation reduction act, drug prices, pharmaceutical Panel – Jen Burke, Mindy McGrath Research & Production – Jen Burke, Mindy McGrath Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this episode, Mindy, Ryan, and Jen discuss recent newsworthy items, including the ruling by Alabama’s Supreme Court that frozen embryos can be legally regarded as “extrauterine children” under state law, and the impact this decision has had on in vitro fertilization (IVF) procedures. They also cover the release of additional guidance from CMS on the Medicare Prescription Payment Plan and a new report from Reuters that revealed the dramatic increase in new drug prices throughout 2023. Podcast Tags: healthcare, healthcare news, IVF, embryos, supreme court, reproductive health, life sciences, health policy, inflation reduction act, CMS, medicare, medicaid, drug prices, pharmaceutical Source Links: The science of IVF: What to know about Alabama\’s \’extrauterine children\’ rulingRare Diseases at FDAPrices for new US drugs rose 35% in 2023, more than the previous year Panel – Jen Burke, Mindy McGrath, Ryan Hummel Research & Production – Anna Briccetti, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this episode, Jack, Ollie, and Jen discuss some recent European-based newsworthy items, covering a prominent oncology society\’s push for tumor classification reform that could have profound impacts on cancer survival rates, the critical need for measles vaccination, and Sweden\’s pioneering use of drones in cardiac arrest intervention. Podcast Tags: healthcare, healthcare news, life sciences, precision oncology, cancer, molecular testing, infectious diseases, vaccination, NHS sustainability, innovation, Sweden Source Links: We’re naming cancers all wrong, oncology leader saysForget lung, breast or prostate cancer: why tumour naming needs to changeRedefining Cancer Classification: A Shift from Organ-based to Molecular-based ApproachA 30-fold rise of measles cases in 2023 in the WHO European Region warrants urgent actionMeasles in Europe: WHO calls for ‘urgent’ vaccinations as cases surgeEurope Needs to Get on Top of Its Measles OutbreakEurope faces resurgence of measles due to low vaccination coverageEurope\’s first transport of blood bags by drone takes place in BelgiumNHS to pioneer drone deliveries in bid to improve serviceDrone chemotherapy becomes an NHS net zero cancer strategySweden uses drones to fight cardiac arrestHealthcare From Above: Challenges And Opportunities Of Medical DronesFlight Trials for Scots Medicine-carrying Drones ConductedGovernment to invest £30 million in innovative technology for NHSDepartment of Health and Social Care: Medical Technology StrategyDrones to deliver NHS medication to care homes and GP surgeries in major roll-outNHS to begin delivering critical medical supplies by drone Panel – Jack Young, Jen Burke, Ollie May Research & Production – Jack Young, Karan Pandya, Ollie May Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

Over the last few years, the MedTech market has been navigating an unpredictable environment due to macro-economic factors and pandemic-driven activity. As we start off 2024, there’s a prevailing feeling that this market is finally starting to stabilize. In this episode, Jen is joined by Vynamic’s Anila Patel and Head of Health Technology Sector, Mary Virzi, to chat about what MedTech moves we’ve seen so far and what we can expect as 2024 kicks into gear. Podcast Tags: healthcare, medtech, product launch, medical device, health tech, healthcare technology Source Links: The biggest stories from the 2024 J.P. Morgan Healthcare Conference5 medtech trends to watch in 2024MEDTECH AND DIAGNOSTICS MARKET: 2023 TRENDS AND 2024 OUTLOOKMedtronic aims to leverage medical device data for AI-enabled care4 heart device trends shaping the medtech sector in 2024J&J\’s Biosense Webster puts forward pulsed field ablation data showing no afib after one yearBoston Scientific nets Farapulse approval, pushes back US TAVR launchJ&J\’s Biosense Webster puts forward pulsed field ablation data showing no afib after one yearMedtronic snags first pulsed field ablation approval in USSpotlight – J&J takes on Medtronic and Boston in pulsed field ablationIncreasing diabetes awareness boosts the diabetes care devices market Panel – Mary Virzi, Anila Patel, Jen Burke Research & Production – Adrea Cope, Everly Petruzzelli Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this episode, Jen sits down with Vynamic’s Deal Activation & Partnership Enablement Service Leads, Senior Director Kevin Fletcher and Executive Sean Martin, to discuss recent newsworthy items coming out of the J.P. Morgan Healthcare Conference, including the major acquisitions and deals announced, particularly those focused on AI and digital innovation. Check out Vynamic’s Deal Activation & Partnership Enablement Service page to learn more about how Vynamic helps clients manage critical, time-sensitive activities across the deal life cycle. Podcast Tags: healthcare, healthcare news, life sciences, pharmaceutical, JP Morgan, deal activation, partnerships, mergers, acquisitions, AI, digital innovation Source Links: Inizio Biotech key takeaways from JPM industry eventCigna sells Medicare business to Health Care Service for $3.3 blnBristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna TherapeuticsJ&J, Merck and Boston Scientific Go on $6.4 Billion Buying SpreeAmazon rolls out digital health benefits program, taps Omada Health as launch partnerWhat the Health Care Sector Was Selling at the J.P. Morgan ConfabJefferson Health says LVHN merger would double its insurance business within 2 years Panel – Jen Burke, Kevin Fletcher, Sean Martin Research & Production – Anna Briccetti, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

Within Life Sciences companies, Medical Affairs teams are tasked with gathering and communicating scientific data, a job that has only grown in importance as therapies have grown more complex and stakeholders have multiplied. Stretched in many directions and under high scrutiny, Medical Affairs teams need to be able to effectively measure and communicate the value of their work. In this deep dive episode, Jen is joined by Gemma Pfister, Head of Life Sciences Europe at Vynamic and Lori Klein, Partner, Medical & Scientific Affairs Practice Lead at Putnam, to discuss what leaders should be thinking about when it comes to measuring impact in Medical Affairs. For more information about the work Putnam does in the Medical Affairs space, visit Putnam’s Medical & Scientific Affairs page. To learn more about Vynamic’s work in Medical Affairs, visit Vynamic’s Medical Affairs page. Podcast Tags: healthcare, life sciences, medical affairs, omnichannel, AI Panel – Gemma Pfister, Jen Burke, Lori Klein Research & Production – Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this episode, Jack, Ollie, and Jen discuss some recent European-based newsworthy items, including the potential impact of Wegovy in reducing excess deaths in the UK, a groundbreaking report on minimising the environmental footprint of surgical care, and Lithuania\’s innovation wave in biotech and MedTech. Podcast Tags: healthcare, healthcare news, life sciences, obesity, medtech, sustainability, biotech, medtech, innovation, lithuania Source Links: Excess mortality in England post COVID-19 pandemic: implications for secondary preventionUK life expectancy falls to lowest level in a decadeExcess deaths involving cardiovascular disease: an analysisWegovy made available in the uk for weight loss in people with prediabetes and type 2 diabetesOur response to serious supply issues of drugs for people with type 2 diabetesMinisters launch £40m pilot scheme to trial wider access to slimming jabHealth Inequalities, Lives, Cut Short, January 2024Can Denmark\’s world-beating drugs maker stay ahead?Landmark report on reducing environmental impact of surgical care publishedGreen Surgery – Reducing the environmental impact of surgical careLithuania Set to Become Home to Largest Biotech CityNorthway Group to build $7.6bn ‘biotech city’ in LithuaniaBaltic-bound: is Lithuania desirable for EU life science investment? Panel – Jack Young, Jen Burke, Ollie May Research & Production – Jack Young, Karan Pandya, Ollie May Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

The US Pharmacy Industry is the largest in the world, with many different players involved in ensuring pharmaceutical products reach consumers. These channels and distribution outlets have drastically changed over the years and will only continue to evolve. The pharmacy channel has reimagined how they are reaching patients, managing risks, and deriving value, expanding their business models beyond dispensing prescription drugs to become wellness destinations. Mindy and Jen are joined by Health Services Heads of Sector, Saurabh Raman and Ryan Hummel, to discuss this complex industry and its evolution. For more information about the work discussed in this episode, check out https://vynamic.com/what-we-do/health-industry/health-services/ Podcast Tags: healthcare, mergers & acquisitions, pharmacy, PBMs, pharmacists, specialty pharmacy, health services Source Links: Market Insights: Pharmacies–Worldwide7 surprising facts about the pharmaceutical industryThe Impact of Pharmaceutical Wholesalers on U.S. Drug SpendingPharmacy Benefit Managers: Practices, Controversies, and What Lies AheadCompetition, Consolidation, and Evolution in the Pharmacy MarketCVS Pharmacy Downsizes: 10 Industry Trends Driving the Retail Shakeout2023 Forecast: Pharmacists push to take on a greater role in patient careA new day in retail pharmacy: The evolving role of pharmacistFive Trends Transforming Pharmacies into Wellness Centers of the FutureCommunity Pharmacists’ Contributions to Disease Management During the COVID-19 PandemicAn Inside Look at Walgreens\’ primary care and pharmacy modelCVS Health completes acquisition of Oak Street HealthCVS launches new venture in biosimilar drug experimentAMA: Don\’t expand scope of practice for already overworked pharmacists Panel – Jen Burke, Mindy McGrath, Ryan Hummel, Saurabh Raman Research & Production – Adrea Cope, Everly Petruzzelli, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this episode, Mindy, Ryan, and Jen discuss recent newsworthy items, including the announcement that Bristol Myers Squibb is purchasing RayzeBio, the use of artificial intelligence in discovering antibiotics that stop MRSA infections, and recent reports revealing an increase in medical errors at hospitals owned by private equity firms. Podcast Tags: healthcare, healthcare news, life sciences, mergers & acquisitions, radiopharma, medtech, artificial intelligence, antibiotics, health services, providers, private equity, hospitals Source Links: BMS enters radiopharma race with $4.1B acquisition of RayzeBio just 3 months after biotech went public‘Explainable’ AI discovers new class of antibiotics that stop MRSA in miceDiscovery of a structural class of antibiotics with explainable deep learningSerious Medical Errors Rose After Private Equity Firms Bought Hospitals Panel – Jen Burke, Mindy McGrath, Ryan Hummel Research & Production – Anna Briccetti, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this special episode, we conclude our annual series on the biggest health industry trends of the next year. Jen sits down with Vynamic Senior Executives Karen Baldry, Mindy McGrath, and Ryan Hummel, and Executives Mary Virzi and Saurabh Raman to discuss the five trends they expect to be most impactful in 2024. These trends include 1) policy implications & judicial decisions, 2) realizing the value of convergence, 3) healthcare as a service, 4) revolutionizing healthcare through AI tech, and 5) next-gen meds. To learn more about Vynamic’s 2024 health industry outlook, visit https://vynamic.com/insights/2024-health-industry-outlook/ Podcast Tags: healthcare, healthcare news, healthcare trends Panel – Jen Burke, Karen Baldry, Mary Virzi, Mindy McGrath, Ryan Hummel, Saurabh Raman Research & Production – Jen Burke, Mindy McGrath Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this special minisode, we continue our annual series on next year’s biggest health industry trends. Jen is joined by Vynamic Executive & Head of Health Technology Mary Virzi to discuss the five MedTech trends Mary expects to be most impactful in 2024. These trends include 1) increased research & development spend, 2) embracing remote patient monitoring, 3) spinoffs to expand access, 4) global regulation and policy shifts, and 5) concentrated mergers and acquisitions. To learn more about Vynamic’s perspective on MedTech, visit https://vynamic.com/insights/2024-medtech-outlook/ Podcast Tags: healthcare, healthcare news, health technology, medtech, healthcare trends Panel – Mary Virzi, Jen Burke Research & Production – Mary Virzi, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

In this special minisode, we continue our annual series on next year’s biggest health industry trends. Jen is joined by Vynamic Senior Executive & Head of Life Sciences Karen Baldry to discuss the five Life Sciences trends Karen expects to be most impactful in 2024. These trends include 1) balancing innovation & affordability, 2) launching for value, 3) breaking down silos, 4) mastering omnichannel, and 5) integrating AI. To learn more about Vynamic’s work in the Life Sciences sector, visit https://vynamic.com/what-we-do/health-industry/life-sciences/ Podcast Tags: healthcare, healthcare news, life sciences, healthcare trends, healthcare innovation, product launch, omnichannel, AI Panel – Karen Baldry, Jen Burke Research & Production – Karen Baldry, Jen Burke Recording & Editing – Mike Liberto, Rachel Skonecki For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.